About mainz biomed nv - MYNZ
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
MYNZ At a Glance
Mainz Biomed NV
Sirius Gutenberg Park
Mainz, Rheinland-Pfalz 55129
| Phone | 49-6131-265140 | Revenue | 893.99K | |
| Industry | Biotechnology | Net Income | -21,650,663.00 | |
| Sector | Health Technology | Employees | 26 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MYNZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.679 |
| Price to Book Ratio | 1.657 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.07 |
| Enterprise Value to Sales | 1.363 |
| Total Debt to Enterprise Value | 2.685 |
MYNZ Efficiency
| Revenue/Employee | 34,384.269 |
| Income Per Employee | -832,717.808 |
| Receivables Turnover | 4.183 |
| Total Asset Turnover | 0.062 |
MYNZ Liquidity
| Current Ratio | 1.318 |
| Quick Ratio | 1.256 |
| Cash Ratio | 1.048 |
MYNZ Profitability
| Gross Margin | -49.458 |
| Operating Margin | -2,060.228 |
| Pretax Margin | -2,421.799 |
| Net Margin | -2,421.799 |
| Return on Assets | -151.154 |
| Return on Equity | -465.818 |
| Return on Total Capital | -232.355 |
| Return on Invested Capital | -382.268 |
MYNZ Capital Structure
| Total Debt to Total Equity | 54.103 |
| Total Debt to Total Capital | 35.108 |
| Total Debt to Total Assets | 24.712 |
| Long-Term Debt to Equity | 14.322 |
| Long-Term Debt to Total Capital | 9.294 |